share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股变动声明-高管 Gibson Christopher
美股SEC公告 ·  06/07 16:09
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals CEO Christopher Gibson completed a series of transactions involving the company's Class A Common Stock on June 5th and 6th, 2024. On June 5th, Gibson acquired 25,000 shares at no cost and disposed of the same number as a bona fide gift. Additionally, he sold 50,000 shares at $8.42 each. The following day, Gibson sold another 50,000 shares, this time at $9.00 per share. After these transactions, Gibson's direct holdings in Recursion Pharmaceuticals totaled 708,738 shares. The total market value of the disposed shares amounted to $871,000.
Recursion Pharmaceuticals CEO Christopher Gibson completed a series of transactions involving the company's Class A Common Stock on June 5th and 6th, 2024. On June 5th, Gibson acquired 25,000 shares at no cost and disposed of the same number as a bona fide gift. Additionally, he sold 50,000 shares at $8.42 each. The following day, Gibson sold another 50,000 shares, this time at $9.00 per share. After these transactions, Gibson's direct holdings in Recursion Pharmaceuticals totaled 708,738 shares. The total market value of the disposed shares amounted to $871,000.
Recursion Pharmaceuticals首席执行官Christopher Gibson于2024年6月5日和6日完成了一系列涉及公司A类普通股的交易。6月5日,Gibson无偿取得了25,000股,并作为真实礼物处置了同样数量的股份。此外,他以每股8.42美元的价格出售了50,000股。第二天,Gibson又以每股9.00美元的价格出售了另外50,000股。这些交易结束后,Gibson在Recursion Pharmaceuticals持有的股份数量共计708,738股。处置的股份的总市值达到871,000美元。
Recursion Pharmaceuticals首席执行官Christopher Gibson于2024年6月5日和6日完成了一系列涉及公司A类普通股的交易。6月5日,Gibson无偿取得了25,000股,并作为真实礼物处置了同样数量的股份。此外,他以每股8.42美元的价格出售了50,000股。第二天,Gibson又以每股9.00美元的价格出售了另外50,000股。这些交易结束后,Gibson在Recursion Pharmaceuticals持有的股份数量共计708,738股。处置的股份的总市值达到871,000美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息